查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095076

帶狀皰疹疫苗市場：全球預測，2026-2032年

Shingles Vaccine Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，帶狀皰疹疫苗市場規模將達到 105.5 億美元，年複合成長率為 12.24%。

主要市場統計數據
基準年 2025 47億美元
預計年份：2026年 52.6億美元
預測年份 2032 105.5億美元
複合年成長率 (%) 12.24%

帶狀皰疹是由水痘帶狀皰疹病毒重新運作引起的，與老齡化和免疫功能下降密切相關。帶狀皰疹構成嚴重的公共衛生負擔，尤其是在50歲以上的成年人和免疫系統較弱的人群中，因為它可能導致帶狀皰疹後遺症神經痛、眼部併發症、住院治療以及長期生活品質下降。重組帶狀皰疹疫苗的出現徹底改變了預防策略，它在老年人群中展現出高效性，並促使政策制定者將重點放在成人免疫、生命全程免疫和基於風險的預防措施上。人口老化、成人免疫指南的擴展、人們對帶狀皰疹後遺症神經痛預防意識的提高以及藥房疫苗供應系統的加強等推動要素了帶狀皰疹疫苗的市場需求。許多國家衛生部門建議老年人接種帶狀皰疹疫苗，一些地區則優先考慮免疫功能低下的成年人，從而構建了一個更結構化、以預防為重點的帶狀皰疹疫苗生態系統。

帶狀皰疹疫苗市場發生變革性變化

帶狀皰疹疫苗接種格局正在經歷結構性轉變，從間歇性成人接種轉向基於指南的計劃性免疫接種。受人口趨勢（例如50歲及以上人口的快速成長）的影響，醫療保健系統日益認知到帶狀皰疹預防是健康老化的一部分。第二個重大變化是從傳統的減毒活病毒疫苗轉向重組非活病毒疫苗。這適用於更廣泛的成人族群，包括許多國家指南中明確指出需要接種的免疫功能免疫力缺乏者。此外，疫苗接種的可近性正在提高，接種系統也正在改變，不再局限於傳統的醫生接種模式，而是透過藥局、基層醫療網路、職業健康計畫和公共衛生宣傳活動等管道進行接種。數位提醒系統、電子健康記錄和免疫接種登記系統透過識別符合接種條件的成年人並鼓勵他們完成兩劑接種，從而減少了錯過接種機會的情況。在保險報銷、醫療專業人員建議和公眾意識一致的情況下，政策推進力度最為強勁。相較之下，在成人免疫基礎設施有限、自費支付存在障礙以及成人疫苗接種率監測系統薄弱的地區，仍存在接種機會不均等的情況。

人工智慧對帶狀皰疹疫苗接種的累積影響

人工智慧 (AI) 正在成為帶狀皰疹疫苗研發、取得、接種和安全監測等各領域的營運驅動力。在臨床和真實世界證據環境中，AI 驅動的分析可以透過結合年齡、免疫抑制狀態、共病、用藥史和醫療保健使用模式等信息，幫助識別高風險族群。在公共衛生營運中，預測模型可以支援優先進行推廣活動、安排預約、庫存規劃和兩劑疫苗依從性計劃，同時最大限度地減少浪費並提高診所的接診能力。自然語言處理可以透過篩檢不利事件報告、科學文獻和安全資料庫來識別需要專家審查的模式，從而支援藥物安全監測。 AI 驅動的病人參與工具還可以支援關於帶狀皰疹風險、疫苗接種時間和療程完成情況的個人化教育，但其使用必須遵守隱私、透明、公平和臨床相關性的標準。這些綜合效應並不能取代臨床決策，但當它們被應用於受監管的醫療保健工作流程時，可以顯著改善成人定向免疫接種、風險分層、服務效率和證據生成。

關於帶狀皰疹疫苗引入的關鍵區域性見解

北美擁有最成熟的成人帶狀皰疹疫苗接種基礎設施，並有針對老年人的既定接種建議。在美國，相關指引涵蓋了19歲及以上因疾病或治療導致免疫力缺乏或免疫抑制，或可能出現免疫功能低下或免疫抑制的成年人。加拿大也制定了系統性的成人免疫接種指南，但各省和地區的實施情況有所不同。在歐洲，各國透過國家免疫技術諮詢流程開展了廣泛的政策舉措，英國、德國、法國、義大利和西班牙等國正逐步將帶狀皰疹疫苗接種納入基於年齡和風險的免疫規劃。然而，關於目標接種年齡、保險報銷和補種疫苗的政策因醫療保健系統而異。亞太地區由於日本、中國、韓國、澳洲和東南亞部分地區人口老化迅速，存在大量未滿足的疫苗接種需求。各國政策制定進度不一，疫苗的可及性取決於監管部門的批准、當地的建議以及保險報銷系統的成熟度。在拉丁美洲，隨著各國加強免疫體系建設，成人免疫的重要性日益凸顯，但疫苗接種率很大程度上取決於公共部門的重視程度、私人醫療服務的可及性以及經濟承受能力。在中東，透過預防性醫療改革和私人醫療服務體系的擴張，成人疫苗接種的重視程度正在提高，這一趨勢在海灣國家的醫療體系中尤其明顯。在非洲，由於感染疾病防治的優先性、資金限制以及成人免疫基礎設施的匱乏，帶狀皰疹疫苗的推廣仍處於起步階段，這些因素影響了公共衛生資源的分配。然而，都市區私營醫療管道的普及和人口老化可能會逐步促進有針對性的疫苗接種。

對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約等主要集團的分析

在東協，帶狀皰疹疫苗的情況各不相同。新加坡和高所得都市區醫療市場成人疫苗接種相對容易，而其他成員國則面臨成本效益、公眾意識和基礎設施的限制。在海灣合作理事會（GCC）國家，加強與預防醫學和生命全程免疫目標的協調，可以透過集中式醫療體系、電子健康記錄和擴大私人醫療服務，更有效地推動成人疫苗接種的整合。歐盟受益於協調的法律規範和強大的藥品安全監測體系，但疫苗接種政策仍由各國自行製定，導致成員國在目標人口、資金籌措和宣傳活動力度方面存在差異。金磚國家的情況各有不同。中國和印度老年人口眾多，醫療服務覆蓋率不斷擴大，但成人免疫接種意識程度參差不齊。巴西在建立全國性疫苗接種基礎設施方面擁有經驗，俄羅斯維持著集中式的公共衛生體系，而南非則面臨與其他醫療挑戰相衝突的優先事項。七國集團（G7）國家通常擁有更完善的成人免疫政策框架、更高的醫護人員意識以及成熟的報銷體系，使其成為循證帶狀皰疹預防策略的重要參考市場。北約成員國與高所得的北美和歐洲醫療體系高度重合，因此越來越重視成人疫苗的穩定供應、健全的供應鏈和公共衛生應急準備；然而，其作為國防聯盟的地位並不必然決定其疫苗政策。

各國帶狀皰疹疫苗策略的關鍵見解

美國擁有最清晰的帶狀皰疹疫苗推薦框架之一，包括對50歲及以上成年人進行常規免疫接種，以及對19歲及以上免疫力缺乏成年人根據風險因素提出接種建議，並輔以藥房接種管道和免疫信息系統。加拿大透過國家指南強調成人免疫接種，但各省和地區的資金決策會影響患者的接種機會。在墨西哥和巴西，由於人口老化和對私人醫療保健的需求，帶狀皰疹疫苗的重要性日益凸顯，但與兒童疫苗和高優先級感染疾病疫苗相比，帶狀皰疹疫苗的公共資金投入仍然有限。英國擁有系統性的全國性帶狀皰疹免疫接種計劃，其特點是基於年齡的接種資格標準和持續的計劃更新。同時，德國、法國、義大利和西班牙則是基於國家和地區層面的建議，這些建議越來越重視老年人和免疫力缺乏人群。俄羅斯的機會在於其集中化的醫療保健管治和人口老化，但公共優先事項較為分散。在中國，由於老年人口規模龐大且都市區成人疫苗的可及性提高，預計長期需求將十分顯著。同時，在印度，由於老年人口基數大規模、私人醫療保健產業不斷發展以及成人預防醫學意識的提高，需求正在逐步擴大。日本由於其超老化社會和完善的醫療保健體系，是一個極為重要的市場。澳洲擁有成熟的免疫決策流程，包括成人疫苗接種建議和公共衛生評估機制。韓國人口老化速度快、醫療保健利用率高且具備數位醫療能力，在良好的保險報銷和指南一致性的環境下，大力支持成人疫苗接種活動。

為帶狀皰疹疫苗行業的領導者提供的實用建議

產業領導者應優先考慮以實證醫學為基礎的成人免疫策略，這些策略應著重解決認知、獲取途徑、依從性和公平性問題，而不應依賴兒童疫苗接種方法。首先，相關人員應加強對臨床醫生關於帶狀皰疹併發症、帶狀皰疹後遺症神經痛預防以及老年人和免疫力缺乏成人合格標準的教育。其次，醫療保健系統應利用電子健康記錄、藥房系統和免疫登記方案來識別符合條件的患者，並提高多劑次接種方案的完成率。第三，公共衛生負責人應透過明確報銷流程、藥房免疫接種、社區宣傳活動以及將接種納入成人常規健康檢查來減少獲取途徑的障礙。第四，溝通應使用清晰的風險效益語言，並符合國家指南，且應針對老年人、看護者和免疫力缺乏患者進行調整。第五，領導者應投資於真實世界證據（REW）項目，以評估疫苗接種率、全程完成率、安全性、有效性以及不同社會經濟和地理群體之間的差異。最後，應加強供應鏈韌性、低溫運輸可靠性和需求計劃，以確保即使在季節性醫療保健需求尖峰時段和大規模疫苗接種宣傳活動期間也能穩定獲得醫療服務。

基於證據的帶狀皰疹疫苗分析的調查方法

本執行摘要基於二手研究和資訊來源，並參考了經核實的公共衛生和科學資源，包括國家免疫指南、監管公告、同行檢驗的醫學文獻、流行病學出版物和公共衛生機構資料。調查方法強調對臨床證據、政策建議、人口統計指標、疫苗接種模式和實際應用趨勢進行三角檢驗。透過已記錄的因素，例如基於年齡的目標人群、免疫力缺乏人群的指南、報銷方案、成人免疫基礎設施、藥房可及性、監測系統和公共衛生優先事項，對區域、人群和國家層面的見解進行解讀。為維持以政策和證據為導向的觀點，本分析不包括市場規模、市場佔有率、商業性預測和公司層面的市場定位。研究結果與已確立的帶狀皰疹臨床研究結果（包括其與老齡化、免疫狀態、帶狀皰疹發病率和併發症風險的關係）檢驗。

結論：透過成人疫苗接種來促進帶狀皰疹的預防。

隨著人口老化、免疫力缺乏人群需求的增加以及帶狀皰疹後遺症神經痛負擔的加重，帶狀皰疹疫苗接種正成為成人醫療保健的核心組成部分。目前的趨勢是轉向重組疫苗策略、基於指南的接種資格標準、藥房疫苗接種計劃以及數據驅動的宣傳活動。區域部署仍不均衡，北美、歐洲部分地區、日本、澳洲和韓國已做好充分準備，而拉丁美洲、中東和非洲以及亞太部分地區的疫苗接種管道和基礎設施尚未完善。合理運用人工智慧可以進一步改善病患識別、藥物依從性、安全監測和資源分配。最有效的策略是將可靠的臨床建議、公平的報銷、數位免疫工具和持續的公眾意識相結合，以提高老化社會帶狀皰疹的預防效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：帶狀皰疹疫苗市場：依疫苗類型分類

  • 重組帶狀皰疹疫苗
  • 帶狀皰疹活疫苗

第8章：帶狀皰疹疫苗市場：依劑量分類

  • 多次給藥
  • 單一劑量

第9章：帶狀皰疹疫苗市場：依年齡層別分類

  • 50-59歲
  • 60-69歲
  • 70歲以上

第10章：帶狀皰疹疫苗市場：依最終用戶分類

  • 診所
    • 當地診所
    • 私人診所
  • 醫院
    • 綜合醫院
    • 專科醫院

第11章：帶狀皰疹疫苗市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第12章：帶狀皰疹疫苗市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：帶狀皰疹疫苗市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章：帶狀皰疹疫苗市場：按國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eagle Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • EVER Pharma Jena GmbH
  • F. Hoffmann-La Roche Ltd.
  • Ferring BV
  • Fresenius SE & Co. KGaA
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • SCHOTT PHARMA AG & CO. KGAA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-563BF1FCEEC2

The Shingles Vaccine Market is projected to grow by USD 10.55 billion at a CAGR of 12.24% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.70 billion
Estimated Year [2026] USD 5.26 billion
Forecast Year [2032] USD 10.55 billion
CAGR (%) 12.24%

Shingles, or herpes zoster, is caused by reactivation of the varicella-zoster virus and is strongly associated with aging and immune compromise. The public health burden is material because shingles can lead to postherpetic neuralgia, ophthalmic complications, hospitalization, and prolonged quality-of-life impairment, particularly among adults aged 50 years and older and immunocompromised populations. Recombinant zoster vaccine has reshaped prevention strategies by demonstrating high efficacy in older adults and by enabling broader policy focus on adult immunization, life-course vaccination, and risk-based protection. Demand drivers in the shingles vaccine landscape include rising aging populations, expanded adult vaccination guidelines, improved awareness of postherpetic neuralgia prevention, and stronger pharmacy-based vaccine delivery. Health authorities in multiple countries recommend shingles vaccination for older adults, while select jurisdictions also prioritize immunocompromised adults, creating a more structured and prevention-oriented shingles vaccine ecosystem.

Transformative Shifts in the Shingles Vaccine Landscape

The shingles vaccine landscape is undergoing a structural shift from episodic adult vaccination toward planned, guideline-driven immunization. Healthcare systems are increasingly recognizing shingles prevention as part of healthy aging, supported by demographic trends showing rapid growth in populations aged 50 years and above. A second major shift is the move from legacy live-attenuated approaches toward recombinant, non-live vaccination strategies, which are suitable for a wider range of adults, including many immunocompromised individuals where clinically indicated by national guidance. Delivery is also changing as pharmacies, primary care networks, occupational health programs, and public health campaigns improve access beyond traditional physician-only settings. Digital reminder systems, electronic health records, and immunization registries are reducing missed opportunities by identifying eligible adults and prompting two-dose completion. Policy momentum is strongest where reimbursement, clinician recommendation, and public awareness align; in contrast, access gaps persist in regions with limited adult immunization infrastructure, out-of-pocket payment barriers, and weaker surveillance of adult vaccine uptake.

Cumulative Impact of Artificial Intelligence on Shingles Vaccination

Artificial intelligence is becoming an operational enabler across shingles vaccine research, access, delivery, and safety monitoring. In clinical and real-world evidence settings, AI-enabled analytics can help identify high-risk cohorts by combining age, immunosuppression status, comorbidities, medication histories, and healthcare utilization patterns. In public health operations, predictive models can support outreach prioritization, appointment scheduling, inventory planning, and two-dose adherence programs while minimizing wastage and improving clinic throughput. Natural language processing can assist pharmacovigilance by screening adverse event narratives, scientific literature, and safety databases for patterns requiring expert review. AI-driven patient engagement tools also support personalized education about shingles risk, vaccine timing, and series completion, though their use must be governed by privacy, transparency, equity, and clinical validation standards. The cumulative impact is not a replacement of clinical decision-making but a measurable improvement in targeted adult immunization, risk stratification, service efficiency, and evidence generation when deployed within regulated healthcare workflows.

Key Regional Insights for Shingles Vaccine Adoption

North America demonstrates the most mature adult shingles vaccination infrastructure, supported by established recommendations for older adults and, in the United States, guidance that includes adults aged 19 years and older who are or will be immunodeficient or immunosuppressed because of disease or therapy. Canada also maintains structured adult immunization guidance, though implementation varies by province and territory. Europe shows broad policy engagement through national immunization technical advisory processes, with countries such as the United Kingdom, Germany, France, Italy, and Spain progressively integrating shingles vaccination into age-based and risk-based programs; however, eligibility ages, reimbursement, and catch-up policies differ across health systems. Asia-Pacific is characterized by high unmet need due to rapid population aging in Japan, China, South Korea, Australia, and parts of Southeast Asia, with policy development advancing at different speeds and access influenced by regulatory approvals, local recommendations, and reimbursement maturity. Latin America is gaining relevance as countries strengthen adult immunization platforms, yet uptake depends heavily on public-sector prioritization, private healthcare access, and affordability. The Middle East is seeing increased attention to adult vaccines through preventive health reforms and expanding private-sector delivery, particularly in Gulf health systems. Africa remains at an earlier stage for shingles vaccination adoption because infectious disease priorities, funding constraints, and limited adult immunization infrastructure shape public health resource allocation, although urban private healthcare channels and aging demographics may gradually support targeted access.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN reflects a diverse shingles vaccine environment in which Singapore and higher-income urban healthcare markets are better positioned for adult vaccination access, while other member states face affordability, awareness, and infrastructure constraints. The GCC is increasingly aligned with preventive healthcare and life-course immunization objectives, with stronger potential for adult vaccine integration through centralized health systems, digital health records, and expanding private care. The European Union benefits from coordinated regulatory oversight and strong pharmacovigilance capacity, but vaccination policy remains nationally determined, leading to differences in eligibility, financing, and campaign intensity across member states. BRICS countries represent a heterogeneous opportunity profile: China and India have large aging populations and expanding healthcare access but variable adult immunization awareness, Brazil has experience with national vaccination infrastructure, Russia maintains centralized public health capacity, and South Africa faces competing healthcare priorities. G7 countries generally show stronger adult immunization policy frameworks, higher clinician awareness, and better reimbursement mechanisms, making them important reference markets for evidence-based shingles prevention strategies. NATO membership overlaps heavily with high-income North American and European health systems where adult vaccine security, resilient supply chains, and public health preparedness are increasingly emphasized, although defense alliance status itself does not determine vaccine policy.

Key Country Insights for Shingles Vaccine Strategies

The United States has one of the clearest shingles vaccine recommendation frameworks, with routine vaccination for adults aged 50 years and older and risk-based recommendations for immunocompromised adults aged 19 years and older, supported by pharmacy access and immunization information systems. Canada emphasizes adult immunization through national guidance, while provincial and territorial funding decisions affect patient access. Mexico and Brazil are building relevance through aging populations and private healthcare demand, though broad public funding for shingles vaccination is more limited than for pediatric and high-priority infectious disease vaccines. The United Kingdom has a structured national shingles immunization program with age-based eligibility and ongoing program updates, while Germany, France, Italy, and Spain rely on national or regional recommendations that increasingly recognize older adults and immunocompromised groups. Russia's opportunity is shaped by centralized healthcare governance and demographic aging, although public prioritization varies. China has substantial long-term need due to the scale of its older adult population and increasing availability of adult vaccines in urban settings, while India's large aging base, expanding private healthcare sector, and improving adult preventive care awareness create gradual demand development. Japan is highly relevant because of its super-aged population and strong healthcare access, and Australia maintains established immunization decision pathways with adult vaccine recommendations and public health evaluation mechanisms. South Korea combines rapid aging, high healthcare utilization, and digital health capabilities, supporting stronger adult vaccination outreach where reimbursement and guideline alignment are favorable.

Actionable Recommendations for Shingles Vaccine Industry Leaders

Industry leaders should prioritize evidence-based adult immunization strategies that address awareness, access, adherence, and equity without relying on pediatric vaccine playbooks. First, stakeholders should strengthen clinician education on shingles complications, postherpetic neuralgia prevention, and eligibility criteria for older and immunocompromised adults. Second, health systems should use electronic health records, pharmacy systems, and immunization registries to identify eligible patients and improve completion of multi-dose schedules. Third, public health planners should reduce access barriers through reimbursement clarity, pharmacy administration, community-based outreach, and integration with routine adult health visits. Fourth, communications should be tailored to older adults, caregivers, and immunocompromised patients using clear risk-benefit language aligned with national guidance. Fifth, leaders should invest in real-world evidence programs that evaluate vaccine uptake, series completion, safety, effectiveness, and disparities across socioeconomic and geographic groups. Finally, supply chain resilience, cold-chain reliability, and demand planning should be strengthened to support consistent access during seasonal healthcare pressures and broader immunization campaigns.

Research Methodology for Evidence-Based Shingles Vaccine Analysis

This executive summary is developed using secondary research and evidence synthesis from verified public health and scientific sources, including national immunization guidelines, regulatory communications, peer-reviewed medical literature, epidemiological publications, and public health agency materials. The methodology emphasizes triangulation across clinical evidence, policy recommendations, demographic indicators, vaccine delivery models, and real-world implementation trends. Regional, group, and country insights are interpreted through documented factors such as age-based eligibility, immunocompromised population guidance, reimbursement structures, adult immunization infrastructure, pharmacy access, surveillance systems, and public health prioritization. The analysis excludes market sizing, market share, commercial forecasts, and company-level positioning to maintain a policy- and evidence-focused perspective. Findings are reviewed for consistency with established clinical understanding of herpes zoster, including the relationship between aging, immune status, shingles incidence, and complication risk.

Conclusion: Advancing Shingles Prevention Through Adult Immunization

Shingles vaccination is becoming a core component of adult preventive healthcare as aging populations, immunocompromised patient needs, and the burden of postherpetic neuralgia intensify policy attention. The landscape is shifting toward recombinant vaccine strategies, guideline-based eligibility, pharmacy-enabled delivery, and data-supported outreach. Regional adoption remains uneven, with North America, parts of Europe, Japan, Australia, and South Korea showing stronger readiness, while Latin America, the Middle East, Africa, and parts of Asia-Pacific present access and infrastructure variability. Artificial intelligence can further improve patient identification, adherence, safety monitoring, and resource allocation when deployed responsibly. The most effective strategies will combine trusted clinical recommendations, equitable reimbursement, digital immunization tools, and sustained public education to improve shingles prevention outcomes across aging societies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Shingles Vaccine Market, by Vaccine Type

  • 7.1. Introduction
  • 7.2. Recombinant Zoster Vaccine
  • 7.3. Zoster Vaccine Live

8. Shingles Vaccine Market, by Dosage

  • 8.1. Introduction
  • 8.2. Multi Dose
  • 8.3. Single Dose

9. Shingles Vaccine Market, by Age Group

  • 9.1. Introduction
  • 9.2. 50 To 59 Years
  • 9.3. 60 To 69 Years
  • 9.4. 70 Years And Above

10. Shingles Vaccine Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
    • 10.2.1. Community Clinics
    • 10.2.2. Private Clinics
  • 10.3. Hospitals
    • 10.3.1. General Hospitals
    • 10.3.2. Specialty Hospitals

11. Shingles Vaccine Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies
    • 11.4.1. Chain Pharmacies
    • 11.4.2. Independent Pharmacies

12. Shingles Vaccine Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Shingles Vaccine Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Shingles Vaccine Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AbbVie Inc.
  • 16.3. Amgen Inc.
  • 16.4. AstraZeneca PLC
  • 16.5. Baxter International Inc.
  • 16.6. Biogen Inc.
  • 16.7. Boehringer Ingelheim International GmbH
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. Chiesi Farmaceutici S.p.A.
  • 16.10. Cipla Limited
  • 16.11. Daiichi Sankyo Co., Ltd.
  • 16.12. Dr. Reddy's Laboratories Ltd.
  • 16.13. Eagle Pharmaceuticals, Inc.
  • 16.14. Eli Lilly and Company
  • 16.15. EVER Pharma Jena GmbH
  • 16.16. F. Hoffmann-La Roche Ltd.
  • 16.17. Ferring B.V.
  • 16.18. Fresenius SE & Co. KGaA
  • 16.19. Gilead Sciences, Inc.
  • 16.20. GlaxoSmithKline PLC
  • 16.21. Glenmark Pharmaceuticals Limited
  • 16.22. Johnson & Johnson Services, Inc.
  • 16.23. Lupin Limited
  • 16.24. Merck & Co., Inc.
  • 16.25. Novartis AG
  • 16.26. Novo Nordisk A/S
  • 16.27. Pfizer Inc.
  • 16.28. Sanofi S.A.
  • 16.29. SCHOTT PHARMA AG & CO. KGAA
  • 16.30. Sun Pharmaceutical Industries Limited
  • 16.31. Teva Pharmaceutical Industries Ltd.
  • 16.32. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHINGLES VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL SHINGLES VACCINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL SHINGLES VACCINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL SHINGLES VACCINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL SHINGLES VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RECOMBINANT ZOSTER VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RECOMBINANT ZOSTER VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RECOMBINANT ZOSTER VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ZOSTER VACCINE LIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ZOSTER VACCINE LIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ZOSTER VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTI DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTI DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTI DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL 50 TO 59 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL 50 TO 59 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL 50 TO 59 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL 60 TO 69 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL 60 TO 69 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL 60 TO 69 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL 70 YEARS AND ABOVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL 70 YEARS AND ABOVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL 70 YEARS AND ABOVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMMUNITY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMMUNITY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMMUNITY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRIVATE CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRIVATE CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRIVATE CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENERAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SPECIALTY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SPECIALTY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SPECIALTY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHAIN PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHAIN PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHAIN PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INDEPENDENT PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INDEPENDENT PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INDEPENDENT PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. NATO SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. NATO SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NATO SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 121. NATO SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. NATO SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. NATO SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 125. NATO SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 127. G7 SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. G7 SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. G7 SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. G7 SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. G7 SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. G7 SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. G7 SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 163. GCC SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GCC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GCC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GCC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 191. JAPAN SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. JAPAN SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. JAPAN SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 194. JAPAN SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. JAPAN SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. JAPAN SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. JAPAN SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. JAPAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. JAPAN SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. INDIA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. INDIA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. INDIA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 203. INDIA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. INDIA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. INDIA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. INDIA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. INDIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. INDIA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. GERMANY SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GERMANY SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 212. GERMANY SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GERMANY SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GERMANY SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 227. AUSTRALIA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 230. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 234. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 236. FRANCE SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. FRANCE SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. FRANCE SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 239. FRANCE SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. FRANCE SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. FRANCE SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. FRANCE SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 243. FRANCE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 245. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. ITALY SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. ITALY SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ITALY SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 257. ITALY SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ITALY SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. ITALY SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 260. ITALY SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. ITALY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. MEXICO SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. MEXICO SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. MEXICO SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 293. MEXICO SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. MEXICO SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. MEXICO SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 308. GLOBAL SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 309. GLOBAL SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025